Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 17, 2018 07:00 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics Announces New Positive Interim Clinical Data and Improvements in Disease Manifestations for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency

Pegzilarginase is Effective in Sustainably Lowering Plasma Arginine Levels Clinically Significant Improvements After Eight Doses Included Effects on Mobility and Adaptive Behavior Company to Host...
October 10, 2018 08:00 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics to Present New Interim Phase 1/2 Clinical Trial Data in Arginase 1 Deficiency at 2018 ASHG Annual Meeting

Company to Host Clinical Update Conference Call on October 17 at 8:30 a.m. ET Aeglea to Present Literature Review on Arginase 1 Deficiency Positive Preclinical Efficacy Data on its AEB4104...
October 01, 2018 08:00 ET | Source: Aeglea BioTherapeutics, Inc.

FDA Grants Rare Pediatric Disease Designation to Pegzilarginase for Arginase 1 Deficiency

Aeglea Eligible to Receive a Priority Review Voucher Company Plans to Initiate Pivotal Trial in First Half of 2019 AUSTIN, Texas, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc....
September 17, 2018 08:00 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics Announces Oral Presentation of Preclinical Data on New Pipeline Therapeutic for Cystinuria at 2018 American Society of Nephrology

AUSTIN, Texas, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics...
September 04, 2018 07:00 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics Announces Positive Interim Clinical Data and Completion of Enrollment for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency

Exceeded Enrollment Target with 15 Patients in Phase 1/2 Trial Additional Interim Data to be Presented at ASHG Conference in October 2018 Company Plans to Announce Pivotal Trial Design in Q4 2018...
August 28, 2018 08:00 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics to Present at 2018 Wells Fargo Healthcare Conference

AUSTIN, Texas, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for...
August 27, 2018 08:00 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics to Present New Interim Phase 1/2 Clinical Trial Data in Arginase 1 Deficiency at 2018 SSIEM Annual Symposium

AUSTIN, Texas, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for...
August 09, 2018 08:00 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results

AUSTIN, Texas, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for...
July 30, 2018 16:00 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics Announces Fall 2018 Medical Conference Schedule

Company Will Provide New Interim Data for Pegzilarginase in Patients with Arginase 1 Deficiency Preclinical Efficacy Data of AEB4104 - a New Enzyme Approach - for the treatment of Homocystinuria ...
July 19, 2018 16:00 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics Appoints Dr. Anthony G. Quinn as President and Chief Executive Officer

AUSTIN, Texas, July 19, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right